Radiopharm Theranostics

RADX · ASX

$1.01+$0.06 (+6.32%)TodayMarket closed · Oct 23, 5:07 PM ET

Prev close $0.95

About RADX

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria and currently employs 14 full-time employees. The company went IPO on 2021-11-25. The firm has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.

Employees: 14
Headquarters: Melbourne, Victoria
Listed: Nov 25, 2021
Sector: Health Care
Industry: Biotechnology
Website: radiopharmtheranostics.com

Leadership

Radiopharm Theranostics executives
Name	Title	Since	Age
Paul Hopper	—	2021	—
Riccardo Canevari	—	—	—
Phillip Hains	—	—	—
Thomas Tulip	—	—	68
Dimitris Voliotis	—	—	60
Leila Alland	—	—	—
Noel Donnelly	—	—	54
Hester Larkin	—	—	—
Ian Turner	—	—	—

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.